ロード中...
Clarithromycin synergizes with cisplatin to inhibit ovarian cancer growth in vitro and in vivo
BACKGROUND: Cisplatin-based chemotherapy is the first-line treatment for ovarian cancer. However, acquired resistance to cisplatin treatment often occurs in epithelial ovarian cancer, and effective and practical methods for overcoming this obstacle are urgently needed. The study aimed to demonstrate...
保存先:
| 出版年: | J Ovarian Res |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6839134/ https://ncbi.nlm.nih.gov/pubmed/31703731 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13048-019-0570-9 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|